Macrovascular disease and atherosclerosis in SSc

Rheumatology

Volumn 47, Issue 5, 2008, Pages 578-583

  Hettema, M E ^a   Bootsma, H ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Atherosclerosis; Macrovascular disease; SSc

Indexed keywords

LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; ENDOTHELIUM LESION; HUMAN; MICROANGIOPATHY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASOSPASM;

ATHEROSCLEROSIS; AUTOIMMUNITY; HUMANS; HYPERLIPIDEMIAS; MIDDLE AGED; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 42949118234     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken078     Document Type: Review

References (155)

1. Ross R. Mechanisms of disease - Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
3. Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJF. Rheumatoid arthritis and macrovascular disease. Rheumatology 2003;42:292-7.
4. del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patents and healthy subjects. Arthritis Rheum 2003;48:1833-40.
5. Gonzalez-Juanatey C, Llorca J, Testa A, Revuelta J, Garcia-Porrua C, Gonzalez-Gay MA. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 2003;82:407-13.
6. Kumeda Y, Inaba M, Goto H et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1489-97.
7. Wallberg-Jonsson S, Ohman M, Rantapaa-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004;33:373-9.
8. De Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Biji M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006;15:675-82.
9. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
10. Karrar A, Sequeira W, Block JA. Coronary artery disease in systemic lupus erythematosus: A review of the literature. Semin Arthritis Rheum 2001;30:436-43.
11. Roman MJ, Shenker B, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
12. Selzer F, Sutton-Tyrrell K, Fitzgerald SG et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004;50:151-9.
13. Vlachoyiannopoulos PG, Kanellopoulos; PG, Ioannidis JPA, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: A controlled study. Rheumatology 2003;42:645-51.
14. De Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005;64:753-9.
15. Herrick AL. Vascular function in systemic sclerosis. Curr Opin Rheumatol 2000;12:527-13.
16. Kahaleh MB, Leroy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 1999;31:195-214.
17. Kahaleh MB. Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 2004;22:S19-23.
18. Leroy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
19. Ioannidis JP, Vlachoylannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
20. Persson J, Stavenow L, Wikstrand J, Israelsson B, Formgren J, Berglund G. Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size. Arterioscler Thromb 1992;12:261-6.
21. The ACAPS Group.Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). Control Clin Trials 1992;13:293-314.
22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986;74:1399-406.
23. Montauban van Swijndregt AD, De Lange EE, De Groot E, Ackerstaff RG. An in vivo evaluation of the reproducibility of intima-media thickness measurements of the carotid artery segments using B-mode ultrasound. Ultrasound Med Biol 1999; 25:323-30.
24. Sramek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: Reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000; 35:699-706.
25. Chong KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002;54:528-38.
26. Norton WL, Nardo JM. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970;73:317-24.
27. Steen V. The heart in systemic sclerosis. Curr Rheumatol Rep 2004;6:137-40.
28. Bulkley BH, Ridolfi AL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. Circulation 1976;53:483-90.
29. Bulkley BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: A clinicopathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 1978;95:563-9.
30. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
31. Leinwand I, Duryee AW, Richter MN. Scleroderma;based on a study of over 150 cases. Ann Intern Med 1954;41:1003-41.
32. Akram MR, Handler CE, Williams M et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology 2006;45:1395-8.
33. Derk CT, Jimenez SA. Acute myocardial infarction in systemic sclerosis patients: A case series. Clin Rheumatol 2007;26:965-8.
34. Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 1992;49:1292-5.
35. Youssef P, Brama T, Englert H, Bertouch J. Limited scleroderma is associated with increased prevalence of macrovascular disease. J Rheumatol 1995;22:469-72.
36. Veale DJ, Collidge TA, Belch JJF. Increased prevalence of symptomatic macrovascular disease in systemic-sclerosis. Ann Rheum Dis 1995;54:853-5.
37. Dick EA, Aviv R, Francis I et al. Catheter angiography and angioplasty in patients with scleroderma. Br J Radiol 2001;74:1091-6.
38. Dabich L, Bookstein JJ, Zweifler A, Zarafonetis CJ. Digital arteries in patients with scleroderma. Arteriographic and plethysmographic study. Arch Intern Med 1972;130:708-14.
39. Janevski B. Arteries of the hand in patients with scleroderma. Diagn Imag Clin Med 1986;55:262-5.
40. Stucker M, Quinna S, Memmel U et al. Macroangiopathy of the upper extremities in progressive systemic sclerosis. Eur J Med Res 2000;5:295-302.
41. Hasegawa M, Nagai Y, Tamura A, Ishikawa O. Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006;155:1159-64.
42. Merkel PA, Herlyn K, Martin RW et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002;46:2410-20.
43. Chung L, Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006;5:125-8.
44. Nihtyanova SI, Brough GM, Black CM, Denton CP. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008;67:120-3.
45. Cheng KS, Tiwari A, Boutin A et al. Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology 2003:42:1299-305.
46. Cheng KS, Tiwari A, Boutin A et al. Differentiation of primary and secondary Raynaud's disease by carotid arterial stiffness. Eur J Vasc Endovasc Surg 2003;25:336-41.
47. Szucs G, Timar O, Szekanecz Z et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis. Relevance for prevention of vascular complications. Rheumatology 2007;46:759-62.
48. Stafford L, Englert H, Gover J, Bertouch J. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis 1998;57:476-9.
49. Bartoli F, Angotti C, Fatini C et al. Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology 2007;46:772-5.
50. Ho ML, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000;59:39-43.
51. Kaloudi O, Basta G, Perfetto F et al. Circulating levels of Nepsilon-(carboxymethyl)-lysine are increased in systemic sclerosis. Rheumatology 2007;46:412-6.
52. Lekakis J, Mavrikakis M, Papamichael C et al. Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon. Am Heart J 1998;136:905-12.
53. Bartoli F, Blagojevic J, Bacci M et al. Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosis. Ann NY Acad Sci 2007;1108:283-90.
54. Cheng KS, Baker CA, Hamilton G, Hooks AP, Seifalian AM. Arterial elastic properties and cardiovascular risk/event. Eur J Vasc Endovasc Surg 2002; 24:383-97.
55. Constans J, Goose P, Pellegrin JL et al. Alteration of arterial distensibility in systemic sclerosis. J Intern Mad 1997;241:115-8.
56. Gosse P, Taillard J, Constans J. Evolution of ambulatory measurement of blood pressure and parameters of arterial stiffness over a 1-year period in patients with systemic sclerosis: ERAMS study. J Hum Hypertens 2002;16:627-30.
57. Moyssakis I, Gialafos E, Vassillou V et al. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology 2005;44:251-4.
58. Andersen GN, Mincheva-Nilsson L, Kazzam E et al. Assessment of vascular function in systemic sclerosis: Indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. Arthritis Rheum 2002;46:1324-32.
59. Constans J, Germain C, Gosse P et al. Arterial stiffness predicts severe progression in systemic sclerosis: The ERAMS study. J Hypertens 2007;25:1900-6.
60. Wan MC, Moore T, Hollis S, Herrick AL. Ankle brachial pressure index in systemic sclerosis: Influence of disease subtype and anticentromere antibody. Rheumatology 2001;40:1102-5.
61. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. J Am Med Assoc 1993;270:465-9.
62. Thatipelli MR, Pellikka PA, McBane RD et al. Prognostic value of ankle-brachial index and dobutamine stress echocardiography for cardiovascular morbidity and all-cause mortality in patients with peripheral arterial disease. J Vasc Surg 2007;46:62-70.
63. Huikuri HV, Mäkikallio T, Alraksinen KEJ, Mitrani R, Castellanos A, Myerburg RJ. Measurement of heart rate variability: A clinical tool or a research toy? J Am Coll Cardiol 1999;34:1878-83.
64. Morelli S, Piccirillo G, Fimognari F et al. Twenty-four heart period variability in systemic sclerosis. J Rheumatol 1996;23:643-5.
65. Ferri C, Emdin M, Giuggioli D et al. Autonomic dysfunction in systemic sclerosis: Time and frequency domain 24 hour heart rate variability analysis. Br J Rheumatol 1997;36:669-76.
66. Pancera P, Sansone S, Presciuttini B et al. Autonomic nervous system dysfunction in sclerodermic and primary Raynaud's phenomenon. Clin Sci 1999;96:49-57.
67. Di Franco M, Paradiso M, Riccieri V, Basili S, Mammarella A, Valesini G. Autonomic dysfunction and microvascular damage in systemic sclerosis. Clin Rheumatol 2007;26:1278-83.
68. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003;108:2093-8.
69. Borba EF, Borges CT, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatol Int 2005;25:379-83.
70. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
71. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: An overview. Free Radic Biol Med 2000;28:1815-26.
72. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006;185:219-26.
73. Expert Panel on Detection EaToHBCiA.Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
74. Koschinsky ML. Lipoprotein(a) and the link between atherosclerosis and thrombosis. Can J Cardiol 2004;20(Suppl B):37B-43B.
75. Lippi G, Guidi G. Lipoprotein(a): An emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003;40:1-42.
76. Lippi G, Caramaschi P, Montagnana M, Salvagno GL, Volpe A, Guidi G. Lipoprotein[a] and the lipid profile in patients with systemic sclerosis. Clin Chim Acta 2006;364:345-8.
77. Herrick AL, Illingworth KJ, Hollis S, Gomez-Zumaquero JM, Tinahones FJ. Antibodies against oxidized low-density lipoproteins in systemic sclerosis. Rheumatology 2001;40:401-5.
78. Piarulli F, Lapolla A, Sartore G et al. Autoantibodies against oxidized LDLs and atherosclerosis in type 2 diabetes. Diabetes Care 2005;28:653-7.
79. Salonen JT, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
80. Goncalves I, Gronholdt ML, Soderberg I et al. Humoral immune response against defined oxidized low-density lipoprotein antigens reflects structure and disease activity of carotid plaques. Arterioscler Thromb Vasc Biol 2005;25:1250-5.
81. Faviou E, Vourli G, Nounopoulos, C, Zachari A, Onyssiou-Asteriou A. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Free Radic Res 2005;39:419-29.
82. Lopes-Virella MF, Virella G, Orchard TJ et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immunol 1999;90:165-72.
83. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler Thromb Vasc Biol 2001;21:269-74.
84. Tinahones FJ, Gomez-Zumaquero JM, Garrido-Sanchez L et al. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res 2005;46:452-7.
85. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995;92:821-5.
86. Arneli S, Hultgardh-Nilsson A, Regnstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996;16:1074-9.
87. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998;18:1972-82.
88. Chyu KY, Reyes OS, Zhao X et al. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (-/-) mice. Atherosclerosis 2004;176:27-35.
89. Yamashita T, Freigang S, Eberle C et al. Maternal immunization programs postnatal immune responses and reduces atherosclerosis in offspring. Circ Res 2006; 99:e51-64.
90. Lopez LR, Simpson DF, Hurley BL, Matsuura E. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: Pathogenic implications for vascular involvement. Ann N Y Acad Sci 2005;1051:313-22.
91. Sherer Y, Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Curr Atheroscler Rep 2001;3:328-33.
92. Assous N, Allanore Y, Batteux F et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 2005;23:199-204.
93. Pope JE, Thompson A. The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 2000;27:1450-2.
94. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576-83.
95. Ihn H, Sato S, Fujimoto M et al. Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996;105:475-9.
96. Picillo U, Migliaresi S, Marcialis MR, Ferruzzi AM, Tirri G. Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity 1995;20:1-7.
97. Herrick AL, Heaney M, Hollis S, Jayson MI. Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis 1994;53:540-2.
98. Lima J, Fonollosa V, Fernandez-Cortijo J et al. Platelet activation, endothelial cell dysfunction in the absence of anticardiolipin antibodies in systemic sclerosis. J Rheumatol 1991;18:1833-6.
99. Passaleva A, Massai G, Matucci-Cerinic M et al. Immunological abnormalities in a group of patients with limited cutaneous systemic sclerosis and prominent vascular disease. Autoimmunity 1990;6:283-91.
100. Sebastian JK, Mahr AD, Ahmed SS et al. Antiendothelial cell antibodies in patients with Wegener's granulomatosis: Prevalence and correlation with disease activity and manifestations. J Rheumatol 2007;34:1027-31.
101. Papadopoulos DP, Makris TK, Krespi P et al. Antiendothelial cell antibody levels in healthy normotensives with high normal blood pressure. Clin Exp Hypertens 2006;28:663-7.
102. Renaudineau Y, Dugue C, Dueymes M, Youinou P. Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002;1:365-72.
103. Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med 1995;238:437-43.
104. D'Cruz DP, Houssiau FA, Ramirez G et al. Antibodies to endothelial cells in systemic lupus erythematosus: A potential marker for nephritis and vasculitis. Clin Exp Immunol 1991;85:254-61.
105. Jones DB, Wallace R, Frier BM. Vascular endothelial cell antibodies in diabetic patients. Association with diabetic retinopathy. Diabetes Care 1992;15:552-5.
106. George J, Meroni PL, Gilburd B, Raschi E, Harats D, Shoenfeld Y. Anti-endothelial cell antibodies in patients with coronary atherosclerosis. Immunol Lett 2000;73:23-7.
107. Belizna C, Duijvestijn A, Hamidou M, Cohen Tervaert JW. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis 2006;65:1545-50.
108. Hebbar M, Lassalle P, Delneste Y et al. Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjogren's syndrome. Ann Rheum Dis 1997;56:230-4.
109. Ihn H, Sato S, Fujimoto M et al. Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol 2000;119:203-9.
110. Renaudineau Y, Revelen R, Levy Y et al. Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol 1999;6:156-60.
111. Carvalho D, Savage CO, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996;97:111-9.
112. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998;25:462-6.
113. Salojin KV, Le TM, Saraux A et al. Antiendothelial cell antibodies: Useful markers of systemic sclerosis. Am J Med 1997;102:178-85.
114. Pignone A, Scaletti C, Matucci-Cerinic M et al. Anti-endothelial cell antibodies in systemic sclerosis: Significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998;16:527-32.
115. Valentini G, Della Rossa A, Bambardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
116. Valentini G, Bencivelli W, Bombardieri S et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003;62:901-3.
117. Tracy RP, Lemaitre RN, Psaty, BM et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-7.
118. Speidl WS, Graf S, Hornykewycz S et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J 2002;144:449-55.
119. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
120. Koenig W, Sund M, Frohlich M et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
121. Folsom AR, Aleksic N, Catellier D, Juneja AS, Wu KK. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2002;144:233-8.
122. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. J Am Med Assoc 1998;279:1477-82.
123. Walker UA, Tyndall A, Czirjak L et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research Group database. Ann Rheum Dis 2007;66:754-63.
124. Hunt BJ. The endothelium in atherogenesis. Lupus 2000;9:189-93.
125. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
126. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
127. Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 2002;41:843-7.
128. Corrado E, Muratori I, Tantillo R et al. Relationship between endothelial dysfunction, intima media thickness and cardiovascular risk factors in asymptomatic subjects. Int Angiol 2005;24:52-8.
129. Anderson ME, Hollis S, Moore T, Jayson MI, Herrick AL. Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 1996;35:1281-8.
130. Anderson ME, Campbell F, Hollis S, Moore T, Jayson MI, Herrick AL. Non-invasive assessment of digital vascular reactivity in patients with primary Raynaud's phenonenon and systemic sclerosis. Clin Exp Rheumatol 1999;17:49-54.
131. Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RIC, Belch JJ. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthritis Rheum 1997;40:352-7.
132. La Civita L, Rossi M, Vagheggini G et al. Microvascular involvement in systemic sclerosis: Laser Doppler evaluation of reactivity to acetylcholine and sodium nitroprusside by iontophoresis. Ann Rheum Dis 1998;57:52-5.
133. Marasini B, Conciato L. Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis. Clin Rheumatol 2001;20:451-2.
134. Sfikakis PP, Papamichael C, Stamatelopoulos KS et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007;56:1985-93.
135. Freedman RR, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud's phenomenon and scleroderma. J Rheumatol 1999;26:2386-8.
136. Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001;28:119-21.
137. Gori T, Di SG, Sicuro S et al. Correlation analysis between different parameters of conduit artery and microvascular vasodilation. Clin Hemorheol Microcirc 2006;35:509-15.
138. Hansell J, Henareh L, Agewall S, Norman M. Non-invasive assessment of endothelial function - relation between vasodilatory responses in skin microcirculation and brachial artery. Clin Physiol Funct Imaging 2004;24:317-22.
139. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27:2292-301.
140. Andersen GN, Caidahl K, Kazzam E et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000;43:1085-93.
141. Cerinic MM, Valentini G, Sorano GG et al. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Semin Arthritis Rheum 2003;32:285-95.
142. Gruschwitz MS, Hornstein OP. von Den DP. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patents with their in situ expression and with disease activity. Arthritis Rheum 1995;38:184-9.
143. Shahin AA, Anwar S, Elawar AH et al. Circulating soluble adhesion molecules in patients with systemic sclerosis: Correlation between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and impaired left ventricular diastolic function. Rheumatol Int 2000;20:21-4.
144. Candell-Riera J, Armandans-Gil L, Simeon CP et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:1138-45.
145. Gustafsson R, Mannting F, Kazzam E, Waldenstrom A, Hallgren R. Cold-induced reversible myocardial ischaemia in systemic sclerosis. Lancet 1989;2:475-9.
146. Long A, Duffy G, Bresnihan B. Reversible myocardial perfusion defects during cold challenge in scleroderma. Br J Rheumatol 1986;25:158-61.
147. Vacca A, Siotto P, Cauli A et al. Absence of epicardial coronary stenosis in patients with systemic sclerosis with severe impairment of coronary flow reserve. Ann Rheum Dis 2006;65:274-5.
148. Kahan A, Nitenberg A, Foult JM et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985;28:637-46.
149. Montisci R, Vacca A, Garau P et al. Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis 2003;62:890-3.
150. Sulli A, Ghio M, Bezante GP et al. Blunted coronary flow reserve in systemic sclerosis: A sign of cardiac involvement in asymptomatic patients. Ann Rheum Dis 2004;63:210-1.
151. Duboc D, Kahan A, Maziere B et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum 1991;34:198-203.
152. Kahan A, Devaux JY, Amor B et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986;314:1397-402.
153. Vignaux O, Allanore Y, Moune C et al. Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis 2005;64:1268-73.
154. Kawano H, Ogawa H. Endothelial function and coronary spastic angina. Intern Med 2005;44:91-9.
155. Ferraccioli G, Di Poi E, DI Gregorio F, Giacomuzzi F, Guerra U. Changes in regional cerebral blood flow after a cold hand test in systemic lupus erythematosus patients with Raynaud's syndrome. Lancet 1999;354:2135-6.